Overall, the trial included patients with cholangiocarcinoma, chondrosarcoma, and 66 patients affected by recurrent IDH1-mut gliomas (thirty-two grade II, eighteen grade III, twelve grade IV, four with unknown grade), that had received a median of two previous systemic therapies (range 1–6), including Temozolomide, Nitrosureas, and Bevacizumab [40] (Table 2). This evidence concerns the gene IDH1 and central nervous system cancer.